rYojbaba Co Ltd
RYojbaba Co Ltd maintains a strong liquidity position, with $6.16 million in cash and equivalents, representing 36.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 6.25%, which is above the industry median of 4.5%, indicating a solid ability to meet short-term obligations. The current ratio of 2.7 further supports this, as it is significantly higher than the industry median of 1.8. Profitability metrics show mixed results. The company reported a net income of $119,390, but operating income was negative at -$755,410, indicating operational inefficiencies. Return on equity (ROE) is 1.96%, which is below the industry median of 4.2%, and return on assets (ROA) is 0.71%, also below the median of 1.5%. These figures suggest that the company is underperforming in terms of capital efficiency and operational returns. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue breakdowns in the latest financials limits the ability to assess the performance of individual business lines. Looking ahead, the company is projected to see a 12.3% increase in revenue in the current fiscal year, with a 7.8% growth expected in the following year. This growth is driven by expansion in service offerings and increased demand in the biotechnology sector. However, the company's operating losses and high price-to-earnings ratio of 326.99 suggest that earnings growth may lag behind revenue growth. Risk factors include the company's negative operating income and high debt-to-equity ratio of 0.69, which is slightly above the industry median of 0.65. While there are no immediate liquidity or dilution flags, the company's reliance on a single revenue stream and the potential for regulatory changes in the healthcare sector pose medium-term risks. Recent filings and transcripts indicate that the company is focusing on cost optimization and expanding its service portfolio. Management has also emphasized the importance of maintaining a strong balance sheet to support future growth initiatives. No significant new risks were identified in the latest disclosures.
Business. RYojbaba Co Ltd operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, primarily generating revenue through service delivery and product sales.
Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.
- RYojbaba Co Ltd has strong liquidity but underperforms in profitability metrics compared to industry medians.
- The company's revenue is concentrated in a single business segment, increasing exposure to regional and regulatory risks.
- Projected revenue growth is positive, but earnings growth is expected to lag due to operational inefficiencies.
- The company maintains a conservative capital structure with no immediate dilution or liquidity risks.
- --
- ## RATIONALES
- ```json
- {
- No immediate filing-based liquidity or dilution flags were detected.